Effect of verapamil on left ventricular function: A randomized, placebo-controlled study

Ronald E. Vlietstra, Maria A.C. Farias, Robert L. Frye, Hugh C. Smith, Erik L. Ritman

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Verapamil has a negative inotropic action in isolated cardiac muscle. Its effects on left ventricular function were tested in 25 patients with suspected coronary artery disease. A double-blind, randomized, placebo-controlled study design was used. Verapamil (0.2 mg/kg over 10 minutes) significantly lowered mean arterial pressure (from 105 to 89 mm Hg) while increasing the cardiac index (from 2.8 to 3.1 liters/min/m2). No statistically significant effect was seen on heart rate, left ventricular end-diastolic pressure or end-systolic volume index, ejection fraction, peak rates of systolic wall thickening or diastolic wall thinning, or percentage of hemiaxial shortening. However, there was a small increase in the left ventricular end-diastolic volume index (from 94 to 102 ml/m2). Important findings were a reduction in systemic vascular resistance (from 39 to 30 U·m2), an increase in left ventricular end-diastolic volume index consistent with a negative inotropic effect, and no evidence of improved regional wall dynamics in portions of the left ventricular wall considered hypokinetic because of myocardial ischemia.

Original languageEnglish (US)
Pages (from-to)1213-1217
Number of pages5
JournalThe American journal of cardiology
Issue number7
StatePublished - Apr 1983

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Effect of verapamil on left ventricular function: A randomized, placebo-controlled study'. Together they form a unique fingerprint.

Cite this